Vinsamlegast notið þetta auðkenni þegar þið vitnið til verksins eða tengið í það: http://hdl.handle.net/1946/16509
Pre-eclampsia is the second most common cause for maternal mortality in the world and causes the death of nearly 46,000 women yearly. It has been connected to maternal morbidity, as well as numerous cardiovascular diseases later in life for the mother. Although much time and resources have been spent on research of the cause and therapy for pre-eclampsia, the pathology of pre-eclampsia still remains a mystery. The only current treatment of pre-eclampsia is premature delivery of the baby and the placenta.
PP13 is a recently discovered placental protein that shows promise as a predictive biomarker for pre-eclampsia. PP13 levels are lower in the serum during the first trimester in women that develop pre-eclampsia later in pregnancy. The effects of this protein during pregnancy are unknown, but the serum levels of the protein increase at the same time that the symptoms of pre-eclampsia emerge.
Our theory is that PP13 has effects on the blood pressure in pregnant women and that it plays a vital part for women with pre-eclampsia. As an attempt to understand the behaviour of the protein, in vivo effects of PP13 and a mutated form of it on blood pressure were researched on foetuses and uterine arteries in 21 gravid rats.
Our results show that PP13 has a lowering effect on blood pressure, increases placental- and pup weight and increases uterine artery width in comparison with a group that was treated with saline. The results also show that PP13 can cause dilation in an artery in vitro. In contrast the PP13 mutant caused limited effect on blood pressure but decreased the pup and placental weights and had only a little effect on dilation in the uterine arteries.
This research gives an idea about the effects of PP13 during pregnancy even though there are many questions to be addressed.